Visual summary
Clonal suppression and organ recovery can diverge in timing. Explain uncertainty and reassess the patient's goals throughout treatment.
Illustration updated October 18, 2026. Educational schematic. Imaging and microscopy panels are illustrations, not patient studies. Full teaching text and sources follow.
Diagram description
Connect clone, protein and tissue injury. Plasma-cell clone — Establish the hematologic process; Light-chain protein — Interpret complementary monoclonal tests; Kidney involvement — Protein loss and tissue evidence; Cardiac involvement — Structure, biomarkers and physiology. Confirm clone and amyloid type separately; follow organ and hematologic responses. The infographic uses anatomical illustrations and integrated labels; the complete teaching text and evidence are below.
Text version
A multisystem diagnostic problem
A plasma-cell clone can produce amyloidogenic light chains that injure several organs. The size of the clone alone does not describe organ risk.
Recognize the combination
Unexplained edema, cardiac dysfunction, autonomic symptoms, proteinuria, or systemic decline may require a unified evaluation.
Confirm clone and tissue type separately
Use serum free light chains plus serum and urine immunofixation to assess a monoclonal process. Tissue amyloid must be typed; a small clone can cause major organ injury, and a coincidental clone does not establish AL. Do not wait for classic multiple-myeloma features before investigating organ-threatening disease.
Check staging inputs exactly
Cardiac staging systems require their specified troponin, natriuretic peptide, and free-light-chain measures. Convert mg/dL to mg/L correctly and distinguish involved/uninvolved ratio from the difference between chains. BNP and NT-proBNP are not interchangeable; massive total proteinuria does not justify inventing an unmeasured dFLC value.
Coordinate specialist care
Hematology, nephrology, cardiology, and pathology should agree on diagnosis, organ staging, and an individualized treatment plan.
Follow parallel responses
Clonal suppression and organ recovery can diverge in timing. Explain uncertainty and reassess the patient's goals throughout treatment.
